New Home Sales in May Leap Higher
The U.S. Census Bureau and the Department of Housing and Urban Development reported Tuesday morning that sales of new homes in May rose to a seasonally adjusted annual rate of 546,000.
The U.S. Census Bureau and the Department of Housing and Urban Development reported Tuesday morning that sales of new homes in May rose to a seasonally adjusted annual rate of 546,000.
The Federal Housing Finance Agency (FHFA) reported this morning that U.S. home prices rose 0.3% month over month in April.
A new research report from Piper Jaffray zeroes in on the firm’s top Focus Calls for investors to buy now.
Carnival released its fiscal second-quarter financial results Tuesday before the markets opened.
The closed-end funds featured in this multi-part report include some tax-free yielding municipal funds, senior loan funds, high-yield funds and even an emerging market debt fund.
PhotoMedex has announced that it will be selling its XTRAC and VTRAC psoriasis and vitiligo treatment businesses to MELA Sciences.
Despite the rush to all-time highs, some top stock picks are turning into top value picks. A new research report from Jefferies highlights value stocks to buy this week.
The U.S. State Department recently approved two sales of military equipment to Lebanon: Tucano turboprop fighter planes and Hellfire II missiles.
Durable goods proved not to be all that durable for the U.S. economy in the month of May.
BlackBerry reported disappointing fiscal first-quarter earnings Tuesday before the market opened, as well as a licensing deal with Cisco Systems.
Tuesday's top analyst upgrades, downgrades and initiations include Newmont Mining, Vodafone, Yelp, Western Digital, American Airlines and AT&T.
UBS is still very positive on the cybersecurity field as a whole, but believe that valuations were frothy now.
One part of the rejected $53 billion offer for Williams Companies from natural gas pipeline MLP Energy Transfer Equity that may turn out worse for investors than the rejection itself is the fate of…
Benitec Biopharma, a clinical-stage biotechnology outfit, has filed for an initial public offering in the United States.
Investors love stock buyback plans. Still, not all share repurchases are created equal. 24/7 Wall St. tracked three standout buyback announcements from Monday.